References
1. Upson K MS. Epidemiology of Adenomyosis. Semin Reprod Med. 2020;38(2-03):89-107.
2. Puente JM FA, Patel J, Patel A, Cerrillo M, Requena A, Garcia-Velasco JA. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol. 2016;2016 ; 20;14(1):60.
3. Younes G TT. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017;108(3):483-490.e3.
4. Vercellini P CD, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. . Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod. 2014;29(5):964-977.
5. Nirgianakis K KD, Schwartz ASK, et al. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a systematic review and meta-analysis. Reprod Biomed Online. 2021;42(1):185-206.
6. Wu Y HJ, Zhong G, Lan J, Lin H, Zhang Q. . Long-term GnRH agonist pretreatment before frozen embryo transfer improves pregnancy outcomes in women with adenomyosis. Reprod Biomed Online. 2021;S1472-6483(21)00528-9.
7. Hou X XJ, Shan H, Mei J, Sun Y, Yan G, Sun H, Wang J. The effect of adenomyosis on IVF after long or ultra-long GnRH agonist treatment. Reprod Biomed Online. 2020;41(5):845-853.
8. Park CW CM, Yang KM, Song IO. . Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clin Exp Reprod Med. 2016;43(3):169-173.
9. Lan J WY, Wu Z, Wu Y, Yang R, Liu Y, Lin H, Jiao X, Zhang Q. Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study. Front Endocrinol (Lausanne). 2021;12:609771.
10. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;46(3):284-98.
11. Bazot M DE. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. Fertility and sterility. 2018;109(3):389-97.
12. Puissant F VRM, Barlow P, Deweze J, Leroy F. . Embryo scoring as a prognostic tool in IVF treatment. Hum Reprod. 1987;2(8):705-8.
13. Man Y BY, Zhao S, Zhao R, Xu X, Wei D et al. The effect of different endometrial preparations on women with polycystic ovary syndrome undergoing initial frozen embryo transfer: A historical cohort analysis. Acta Obstet Gynecol Scand. 2021;100:1116-23.
14. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. American journal of obstetrics and gynecology. 1982;144(6):655-60.
15. Thalluri V TK. Ultrasound diagnosed adenomyosis has a negative impact on successful implantation following GnRH antagonist IVF treatment. Hum Reprod Update. 2012;27(12):3487-3492.
16. Kolanska K CJ, Bendifallah S, Selleret L, Antoine JM, Chabbert-Buffet N, Darai E, d’Argent EM. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist. J Gynecol Obstet Hum Reprod. 2017;46(9):681-686.
17. Sheng Y MC, Yang R, Liu Z, Liu P, Qiao J. Effects of Different Controlled Ovarian Hyperstimulation for Adenomyosis on the Outcomes of IVF-ET. Reprod Contracept. 2010;30(6):375–8.
18. Khan KN KM, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. . Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25(3):642-53.
19. Tremellen K RP. Adenomyosis is a potential cause of recurrent implantation failure during IVF treatment. Aust N Z J Obstet Gynaecol. 2011;51(3):280-3.